NYSE: STESteris PLC Stock
$224.74+0.70 (+0.31%)
Updated Apr 30, 2025
STE Price
$224.74
Fair Value Price
N/A
Market Cap
$22.08B
52 Week Low
$200.98
52 Week High
$248.24
P/E
47.41x
P/B
3.44x
P/S
3.98x
PEG
1.33x
Dividend Yield
0.99%
Revenue
$5.10B
Earnings
$467.59M
Gross Margin
43.4%
Operating Margin
14.73%
Profit Margin
9.2%
Debt to Equity
0.56
Operating Cash Flow
$1B
Beta
0.78
Next Earnings
May 14, 2025
Ex-Dividend
N/A
Next Dividend
N/A
STE Overview
STERIS PLC provides products and services to prevent infections in patients. Products include capital equipment (sterilizers and washers, surgical tables, lights and equipment management systems) and connectivity solutions (operating room integration), consumables (detergents and gastrointestinal endoscopy accessories), and dental instruments. Services offered include equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory services and off-site reprocessing. STERIS was founded in 1985 and is based in Dublin, IE.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STE's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
STE
Ranked#21 of 108
Ranked#21 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.31 | A | |
| $23.03 | A | |
| $14.12 | A |
Be the first to know about important STE news, forecast changes, insider trades & much more!
STE News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STE ($224.74) is trading above its intrinsic value of $87.22, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STE is poor value based on its earnings relative to its share price (47.41x), compared to the US market average (29.18x)
P/E vs Market Valuation
STE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more STE due diligence checks available for Premium users.
Valuation
STE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
47.41x
Industry
37.39x
Market
29.18x
STE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
STE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
STE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.44x
Industry
3.94x
STE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STE price to earnings growth (PEG)
For valuing profitable companies with growth potential
STE is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
STE's financial health
Profit margin
Revenue
$1.4B
Net Income
$173.5M
Profit Margin
12.7%
STE's Earnings (EBIT) of $750.30M... subscribe to Premium to read more.
Interest Coverage Financials
STE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.0B
Liabilities
$3.6B
Debt to equity
0.56
STE's short-term assets ($1.90B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STE's long-term liabilities ($2.69B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
STE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$332.8M
Investing
-$123.9M
Financing
-$214.4M
STE's operating cash flow ($1.14B)... subscribe to Premium to read more.
Debt Coverage Financials
STE vs Medical Device Stocks
Steris Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.